Plasma protease C1-inhibitor treatment involves administering human plasma-derived C1-inhibitor concentrate to treat hereditary angioedema (HAE). HAE is a rare genetic disorder caused due to low levels of the C1-inhibitor protein in blood that leads to recurrent skin swelling, laryngeal edema, and abdominal pain.
The global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 5432.28 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The growing prevalence of hereditary angioedema globally is expected to drive the plasma protease C1-inhibitor treatment market growth over the forecast period. According to a report by HAEi (U.S. Hereditary Angioedema Association), HAE affects approximately 1 in 10,000 to 1 in 50,000 people worldwide. Moreover, as per National Organization for Rare Disorders (NORD), approximately 1 in 50,000 people in the United States have HAE. Early diagnosis and prevention of recurrent HAE attacks is important to avoid potentially life-threatening airway swelling. Plasma protease C1-inhibitor treatment provides on-demand therapy to patients and helps to prevent HAE attacks, thereby boosting the market growth. Further, ongoing research and development of long acting drugs for prophylactic treatment of HAE is also anticipated to present lucrative opportunities in the market during the forecast period.
The global Plasma Protease C1-inhibitor Treatment market is segmented into Hereditary Angioedema (HAE) and Acquired Angioedema. Hereditary Angioedema is currently the dominant segment as it is the primary disease condition treated by plasma protease C1-inhibitor. HAE affects approximately 1 in 10,000 to 1 in 50,000 people globally and causes recurring attacks of swelling that can affect various body parts including arms, legs, face, intestinal tract, and airway. If left untreated, HAE attacks may cause asphyxiation.
Political: The market is subject to stringent regulations pertaining to plasma-derived therapy approval and reimbursement policies that differ across countries and regions.
Economic: Rising healthcare expenditures coupled with increasing patient awareness levels is expected to drive market growth over the forecast period.
Social: Growing emphasis on rare disease treatment and prevention of fatality risk are major social factors propelling the market.
Technological: Advancements in protein engineering and gene therapy approaches are promising areas that could supplement existing plasma-based treatment options in the future.
The Global Plasma Protease C1-Inhibitor Treatment Market Growth is expected to witness high at a CAGR of 18% during the forecast period of 2023 to 2030. The global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 5432.28 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030.
Regionally, North America commands the largest market share currently due to advanced healthcare systems and availability of therapies. Europe is also a major regional market propelled by supportive regulatory environment and focus on orphan drugs.
Key players operating in the Plasma Protease C1-inhibitor Treatment are CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc. CSL Behring LLC dominates with its products Berinert and Haegarda approved for prophylactic treatment of HAE. Takeda Pharmaceutical’s Takhzyro is a subcutaneous C1-inhibitor concentrate also effective for HAE prevention. Ionis Pharmaceuticals’ investigational drug candidate IONIS-PKK-L Rx aims gene silencing approach for treatment.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it